Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Chimin Health Management Co., Ltd. (603222.SS)
Taizhou, CN
Chimin Health Management Co., Ltd., formerly known as Zhejiang Chimin Pharmaceutical Co.,Ltd., is a Chinese enterprise specializing in the research, production, and distribution of pharmaceuticals for human use and medical apparatus. Its product offerings include diverse medical packaging options, such as non-PVC soft bags with various valve configurations (e.g., double-tube double valves, single valves, single-tube double valves), plastic bottles, and other specialized containers. The company also supplies an extensive array of injection and infusion devices, encompassing safety syringes, safety injection needles, sterile syringes, irrigators, dispensers, insulin syringes, as well as standard and precision filter infusion sets. Beyond these, Chimin Health Management provides in-vitro diagnostic products, hemodialysis supplies, and delivers medical services. The firm was established in 1996 and maintains its principal operations in Huangyan, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.66% | -10.22% | -10.41% | -6.20% | -10.59% | -3.83% | +42.07% | -29.48% | -23.94% | -6.20% | +131.92% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%-11.9% Q1'26: -9.9% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-327.3% Q1'26: -68.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-18.6% Q1'26: +2.9% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%-22.4% Q1'26: -10.5% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%-8.8% Q1'26: -4.0% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-3.7% ★ Q1'26: +13.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×-22.20× Q1'26: -11.55× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|
| Revenue |
837.24M
est: 854.00M (-2.0%)
|
894.51M
est: 1.21B (-26.0%)
|
775.73M
est: 1.62B (-52.1%)
|
683.60M
est: 2.05B (-66.7%)
|
| EBITDA |
145.25M
est: 131.43M (+10.5%)
|
64.91M
est: 186.06M (-65.1%)
|
54.25M
est: 172.93M (-68.6%)
|
-32.79M
est: 219.26M (-115.0%)
|
| EBIT |
70.36M
est: 40.21M (+75.0%)
|
-25.36M
est: 56.93M (-144.5%)
|
-44.73M
est: -10.25M (-336.3%)
|
-153.15M
est: -13.00M (-1,078.2%)
|
| Net Income |
34.46M
est: 38.00M (-9.3%)
|
-65.48M
est: 189.99M (-134.5%)
|
-59.71M
est: 266.48M (-122.4%)
|
-245.58M
est: 381.44M (-164.4%)
|
| SGA |
258.96M
est: 172.20M (+50.4%)
|
293.60M
est: 243.79M (+20.4%)
|
276.71M
est: 512.30M (-46.0%)
|
233.89M
est: 649.55M (-64.0%)
|
| EPS |
0.07
est: 0.07 (+0.0%)
|
-0.12
est: 0.35 (-134.3%)
|
-0.11
est: 0.51 (-121.6%)
|
-0.47
est: 0.73 (-164.4%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 4.8K | 0.48% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 10.8K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 532.3K | 0.06% |
| 4 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 855.30 | 0.22% |
| 5 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.6K | 0.22% |
| 6 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.4K | 0.22% |
| 7 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 610.30 | 0.22% |
| 8 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 70.47 | 0.22% |
| 9 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 23.16 | 0.31% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 11.03 | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gao Peng Qiu | Executive Vice President & Director | — | male |
| Hewei Wang | Accounting Supervisor | — | — |
| Kun Chen | Director, Vice President & Board Secretary | — | male |
| Qinghong He | Vice President | — | female |
| Yang Guowei | Financial Director | — | male |
| Yong Bie | Vice President | — | male |
| Yunfei Tian | President & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603222.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
